PQA has begun developing a health plan performance measure for chronic obstructive pulmonary disease (COPD). COPD is a high-burden and expensive condition, so ensuring effective, high-quality treatment is a priority for patients and those who care for them.
PQA, the Pharmacy Quality Alliance, has begun developing a health plan performance measure for chronic obstructive pulmonary disease (COPD).
As the summer winds down, we are quickly approaching the end of 2022. PQA has been busy this year, in collaboration with our members, advancing the quality of medication use through measure development and stewardship, education, research and convening.
The PQA Quality Essentials Webinar provides education on the fundamentals of quality measurement, which is important for effective measure implementation and performance, and information about where and how PQA quality measures are used.
We are excited to announce that we will be open registration for the 2022 PQA Leadership Summit later this month. This year's summit will take place November 10-11 in Arlington, Va., and explore quality and value in medication use from patient, provider, purchaser, payer and industry perspectives.
PQA follows a systematic, transparent and consensus-based development process to ensure that measures are important, scientifically acceptable, feasible and usable. However, the measurement lifecycle does not end when a measure is endorsed.
This guest blog is one in a series by sponsors of the 2022 PQA Annual Meeting on the utilization of the EQUIPP platform to promote performance improvement on medication-related quality measures while engaging transparency between health plans and pharmacies. The views shared in this series are those of the author and do not reflect any PQA positions.
Quality measures are standards for measuring the performance of health care providers to care for patients and populations. PQA develops and stewards measures focused on medication use.
Recently published research conducted by the National Pharmaceutical Council, PQA and the University of Rhode Island measured the impact of patient nonadherence to oral anticancer medications. The study findings have been published in the Journal of Managed Care & Specialty Pharmacy.
The PQA Postdoctoral Executive Fellowship helps produce the next generation of leaders in health care quality through a full-time, 12-month program. Executive Fellows collaborate with PQA staff, members and other stakeholders on a variety of initiatives to improve medication use quality. During the fellowship, individuals will expand their skills and experience in project management, quality measure design and implementation, non-profit administration and association management, and health care quality research.
Biopharmaceutical innovation has led to an increase in the availability of oral medications to treat cancer. Oral anticancer medications (OAMs) are much more convenient for patients and avoid the inconvenience and administration costs of having to receive treatment at a doctor’s office or outpatient infusion center, allowing patients to self-administer oral medication at home. One challenge with OAMs however is nonadherence. Research has shown that almost half of patients on OAMs do not take their medications as prescribed.
PQA’s Board of Directors represents a diverse group of thought leaders and experts in healthcare, who understand how medication optimization improves patient outcomes and supports a value-based care system. Their expertise helps PQA advance the safe and appropriate use of medicines. This blog is one in a series profiling PQA's Board members.
Each month PQA hosts a Quality Forum Webinar which focuses on best practices and emerging trends in medication use quality, medication services and other initiatives that can improve health care quality.
PQA provides healthcare quality experience to students from a wide variety of disciplines. This summer, we are hosting three students through our PQA Summer Executive Internship sponsored by Pharmacy Quality Solutions and MPH practicum program.
This guest blog is one in a series by sponsors of the 2022 PQA Annual Meeting on the application of measures into daily practice. The views shared in this series are those of the author and do not reflect any PQA positions
At PQA, our research develops evidence to support meaningful quality measures, demonstrates the value of medications and pharmacist-provided care, and fosters collaboration within the healthcare system to address social determinants of health (SDOH) and improve medication access.
The PQA Quality Forum Webinar is a regular, recurring series on healthcare quality topics with a focus on medication use and medication services. It is a forum for educating and engaging with PQA members and quality-focused healthcare professionals.
PQA’s Board of Directors represents a diverse group of thought leaders and experts in healthcare, who understand how medication optimization improves patient outcomes and supports a value-based care system. Their expertise helps PQA advance the safe and appropriate use of medicines. This blog is one in a series profiling PQA's Board members.
Healthcare providers increasingly recognize the importance of social determinants of health (SDOH). PQA is exploring the role of pharmacists and pharmacy services in addressing patients’ SDOH, including SDOH screenings and additional services that address barriers to medication access and increase medication adherence. Although there is a growing focus on SDOH in healthcare, there is little information on how organizations collect and use SDOH data to support patient care and outcomes.
This past January, PQA published the first edition of the PQA Social Determinants of Health Resource Guide. The guide features 20 real-world SDOH services that are promising for improving the quality and safety of medication use.
